Last reviewed · How we verify

placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan

Montefiore Medical Center · FDA-approved active Small molecule

This combination product uses an antihistamine, decongestant, and cough suppressant to reduce cold and cough symptoms through multiple pathways.

This combination product uses an antihistamine, decongestant, and cough suppressant to reduce cold and cough symptoms through multiple pathways. Used for Common cold symptoms including cough, nasal congestion, and sneezing, Cough suppression associated with upper respiratory infections.

At a glance

Generic nameplacebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan
SponsorMontefiore Medical Center
Drug classCombination cold and cough remedy
TargetH1 receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); sigma-1 receptor and NMDA receptor (dextromethorphan)
ModalitySmall molecule
Therapeutic areaRespiratory/Cold and Cough
PhaseFDA-approved

Mechanism of action

Diphenhydramine is a first-generation antihistamine that blocks H1 receptors to reduce histamine-mediated symptoms like itching and sneezing. Phenylephrine is an alpha-1 adrenergic agonist that causes vasoconstriction to relieve nasal congestion. Dextromethorphan is a non-opioid cough suppressant that acts on the cough center in the medulla. The placebo component serves as a control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: